

Press Release

For Immediate Dissemination

**Glenmark's Consolidated Net Profit increases by 48.38% to Rs. 1703 Mn
in Q3 FY 15-16****Consolidated Revenue increases by 4.53% to Rs. 17,782.96 Mn****Consolidated EBITDA increases by 39.19% to Rs. 3697.62 Mn****Business Highlights Q3 FY 15-16:**

- US Business grew by 20.04% to Rs. 6,088.68 Mn
- India Business grew by 12.69% to Rs. 4,880.30 Mn
- Rest of the World (ROW) Business grew by 14.09% to Rs. 2,363.39 Mn

Mumbai – January 28, 2016: Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company today announced its results for the third quarter and nine months ended December 31, 2015.

For the third quarter ended December 31, 2015, Glenmark's consolidated revenue was at Rs. 17,782.96 Mn (USD 270.15 Mn) as against Rs. 17,013.07 Mn (USD 274.80 Mn) recording an increase of 4.53%.

Consolidated Net Profit for Q3 FY 15-16 was Rs. 1703 Mn as compared to Rs. 1147.73 Mn in the previous corresponding quarter; an increase of 48.38%. Consolidated EBITDA was at Rs. 3697.62 Mn in Q3 FY 15-16 as compared to Rs. 2656.61 Mn in the previous corresponding period; an increase of 39.19%

"We have recorded good overall growth in the quarter powered by our India and US businesses. The devaluation of currencies across emerging markets continues to impact our operations; although we have registered good growth in local currencies in our key emerging markets. Going ahead, we expect our India, US and Europe businesses to continue to drive growth for our company;" said **Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited.**

For the nine months ended Dec 31, 2015, Glenmark's consolidated revenue was at Rs. 53,429.07 Mn as against Rs. 48,689.55 Mn; an increase of 9.73% over the previous corresponding period.

India

Sales for the formulation business in India for the third quarter ended December 31, 2015, was at Rs. 4,880.30 Mn (USD 73.99 Mn) as against Rs. 4,330.73 Mn (USD 69.82 Mn) in the previous corresponding quarter, recording growth of 12.69%.

USA Formulations

Glenmark Pharmaceuticals Inc., U.S.A. registered revenue from the sale of finished dosage formulations was at Rs. 6,088.68 Mn (USD 92.58 Mn) for the third quarter ended December 31, 2015 against revenue of Rs. 5,072.01 Mn (USD 81.82 Mn) for the previous corresponding quarter, recording an increase of 20.04%.

Africa, Asia and CIS Region (ROW)

For the third quarter, revenue from Africa, Asia and CIS region was Rs. 2,363.39 Mn (USD 36.05 Mn) as against Rs. 2,071.49 Mn (USD 33.48 Mn) for the previous corresponding quarter, recording an increase of 14.09%.

Europe Formulations

Glenmark Europe's operations revenue for the third quarter ended December 31, 2015 was at Rs. 1,763.53 Mn (USD 26.91 Mn) as against Rs. 1,729.54 Mn (USD 28.08 Mn) in the previous corresponding quarter recording growth of 1.97%.

Latin America

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 1,237.26 Mn (USD 18.61 Mn) for the third quarter ended December 31, 2015 as against Rs. 2,344.40 Mn (USD 38.00 Mn).

Active Pharmaceutical Ingredients (API)

Revenue from sale of API business globally was Rs. 1,449.80 Mn (USD 22.01 Mn) for the quarter ended December 31, 2015 as against Rs. 1,464.90 Mn (USD 23.60 Mn) for the previous corresponding quarter.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered in Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies in the world in terms of revenues. (SCRIP 100 Rankings 2016). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of oncology, Inflammation [asthma/COPD, rheumatoid arthritis etc.] and pain [neuropathic pain and inflammatory pain]. Glenmark has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiaries has 16 manufacturing facilities in five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western Europe markets. The API (active pharmaceutical ingredient) business sells its products in over 80 countries, including the US, various countries in the EU, Latin America and India.

For further information, please contact:

Jason D'Souza/Rajdeep Barooah

Glenmark, Mumbai, India

Tel: [+91 22] 40189919/984**Email:** corpcomm@glenmarkpharma.com